Werfen has successfully completed the acquisition of Immucor after obtaining all necessary regulatory and antitrust approvals.

Immucor is a privately held, U.S.-based company, in the in vitro diagnostics (IVD) sector, with a global presence in the transfusion and transplant markets.

“During our more than 50-year history, we have demonstrated our strong commitment to expand our IVD business through organic growth, complemented with highly strategic acquisitions,” says Carlos Pascual, CEO of Werfen.

The price of the acquisition was approximately $2 billion, financed by a combination of cash on-hand and bank debt facilities, syndicated by 19 national and international entities, led by BBVA, BNP Paribas, CaixaBank and HSBC.

As part of its credit management, Werfen plans to refinance part of the debt in the capital markets, as well as quickly reduce the level of indebtedness. Following the announcement of the acquisition, Standard & Poor’s affirmed Werfen’s investment grade rating (BBB-) with a stable outlook, the company says.

With the integration of Immucor, Werfen says it is set to expand its presence as a company of reference in the specialized diagnostics market and grows its portfolio of diagnostic solutions for hospitals and clinical laboratories.

The company says it will have seven technology centers and employ more than 7,000 people worldwide; with a direct presence in more than 30 countries and in more than 100 territories through distributors.